Zalecenia dotycz?ce oceny schorzeń wspó?istniej?cych u chorych na przewlek?? bia?aczk? szpikow? w procesie wyboru inhibitora kinaz tyrozynowych

作者：TomaszSacha; SebastianSzmit; DorotaZozulińska Ziókiewicz; WitoldPrejzner; JoannaGóra Tybor

来源：Acta Haematologica Polonica, 2016, 47(3): 184-196.

DOI：10.1016/j.achaem.2016.06.001

• Chronic myeloid leukemia
• Tyrosine kinase inhibitors
• Co-morbidities

Abstract(#br)Treatment of chronic myeloid leukemia with tyrosine kinase inhibitors (TKI) is very effective. The vast majority of patients achieve deep and long-lasting therapeutic responses including those on molecular level. Understanding the adverse effects of TKIs is of great importance during li...